Researchers at Kowa Company Co. Ltd. Target Biomarkers (Effects of Pemafibrate On Ldl-c and Related Lipid Markers In Patients With Masld: a Sub-analysis of the Pema-fl Study).

Researchers at Kowa Company Co. Ltd. conducted a sub-analysis of the PEMA-FL study, focusing on the effects of pemafibrate on LDL-C and related lipid markers in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The study found that pemafibrate significantly reduced LDL-C levels in patients with MASLD, particularly in those with higher baseline LDL-C levels. The research suggests that pemafibrate may benefit patients with MASLD by improving LDL-C levels and the LDL particle profile. [Extracted from the article]